rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
3
|
pubmed:dateCreated |
1999-7-12
|
pubmed:abstractText |
Many patients with advanced NHL ultimately relapse and require salvage treatment. Oxaliplatin, a diaminocyclohexane (DACH) platinum, has shown a differential spectrum of cytotoxicity with cisplatin, with activity in primary or secondary cisplatin-resistant solid tumors (colon and ovarian cancer). We report the tolerance/activity of this platinum derivate in previously-treated NHL patients.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0923-7534
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
351-4
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:10355582-Adult,
pubmed-meshheading:10355582-Aged,
pubmed-meshheading:10355582-Antineoplastic Agents,
pubmed-meshheading:10355582-Dose-Response Relationship, Drug,
pubmed-meshheading:10355582-Drug Administration Schedule,
pubmed-meshheading:10355582-Drug Resistance, Neoplasm,
pubmed-meshheading:10355582-Female,
pubmed-meshheading:10355582-Humans,
pubmed-meshheading:10355582-Infusions, Intravenous,
pubmed-meshheading:10355582-Lymphoma, Non-Hodgkin,
pubmed-meshheading:10355582-Male,
pubmed-meshheading:10355582-Middle Aged,
pubmed-meshheading:10355582-Neoplasm Recurrence, Local,
pubmed-meshheading:10355582-Organoplatinum Compounds,
pubmed-meshheading:10355582-Pilot Projects,
pubmed-meshheading:10355582-Prognosis,
pubmed-meshheading:10355582-Salvage Therapy,
pubmed-meshheading:10355582-Treatment Outcome
|
pubmed:year |
1999
|
pubmed:articleTitle |
Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients.
|
pubmed:affiliation |
Fédération des Maladies Sanguines, Immunitaires et Tumorales, Hôpital Paul Brousse, Villejuif, France.
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|